This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

The claimed invention is:

1. A compound of the formula I:



I

wherein

A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or =CR-CR=CR-N=;

R_1 is selected from the group consisting of:

- hydrogen;

-C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20}alkyl)$_{0-1}$-aryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$ -C_{1-20} alkyl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; and

-C_{1-20} alkyl-NR_3-Q-X-R_4 or -C_{2-20} alkenyl-NR_3-Q-X-R_4 wherein **Q** is –CO- or –SO_2-; **X** is a bond, -O- or -NR_3- and $\mathbf{R_4}$ is aryl; heteroaryl; heterocyclyl; or -C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisiting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20}alkyl)$_{0-1}$-aryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$ -C_{1-20} alkyl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-$N(R_3)_2$;

-NR_3-CO-O-C_{1-20}alkyl;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; or R_4 is



wherein **Y** is –N- or –CR-;

R_2 is selected from the group consisting of:

-hydrogen;

-C_{1-10} alkyl;

-C_{2-10} alkenyl;

-aryl;

-C_{1-10} alkyl -O-C_{1-10}-alkyl;

-C_{1-10} alkyl-O-C_{2-10} alkenyl; and

-C_{1-10} alkyl or C_{2-10} alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-CO-$N(R_3)_2$;

-CO-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each R_3 is independently selected from the group consisting of hydrogen and C_{1-10} alkyl; and

each **R** is independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, halogen and trifluoromethyl,

or a pharmaceutically acceptable salt thereof.

2. A compound according to Claim 1 wherein R_1 is selected from the group consisting of C_{1-6} alkyl and C_{1-6} hydroxyalkyl.

3. A compound according to Claim 2 wherein R_1 is selected from the group consisting of n-butyl, 2-hydroxy-2-methylpropyl, and 2-methylpropyl.

4. A compound according to Claim 1 wherein R_2 is selected from the group consisting of C_{1-6} straight chain alkyl and alkoxyalkyl wherein the alkoxy moiety and the alkyl moiety each independently contain 1 to 4 carbon atoms.

5. A compound according to Claim 4 wherein R_2 is selected from the group consisting of methyl, n-butyl, benzyl, ethoxymethyl, and methoxyethyl.

6. A compound according to Claim 1 wherein each R is hydrogen.

7. A compound according to Claim 1 wherein R_1 is $-C_{1-20}$ alkyl-NR_3-Q-X-R_4.

8. A compound according to Claim 7 wherein R_4 is



9. A compound according to Claim 1 wherein A is =CH-CH=CH-N=.

10. A compound of the formula II:



II

wherein

B is -NR-$C(R)_2$-$C(R)_2$-$C(R)_2$-; -$C(R)_2$-NR-$C(R)_2$-$C(R)_2$-; -$C(R)_2$-$C(R)_2$-NR-$C(R)_2$- or -$C(R)_2$-$C(R)_2$-$C(R)_2$-NR-;

$\mathbf{R_1}$ is selected from the group consisting of:

- hydrogen;

-C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20}alkyl)$_{0-1}$-aryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$ -C_{1-20} alkyl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-$N(R_3)_2$;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; and

-C_{1-20} alkyl-NR_3-Q-X-R_4 or -C_{2-20} alkenyl-NR_3-CO-X-R_4 wherein **Q** is –CO- or –SO_2-; **X** is a bond, -O- or -NR_3- and $\mathbf{R_4}$ is aryl; heteroaryl; heterocyclyl; or -C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20}alkyl)$_{0-1}$-aryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$ -C_{1-20} alkyl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-NR_3-CO-O-C_{1-20}alkyl;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; or R_4 is



wherein **Y** is –N- or –CR-;

R_2 is selected from the group consisting of:

-hydrogen;

-C_{1-10} alkyl;

-C_{2-10} alkenyl;

-aryl;

-C_{1-10} alkyl -O-C_{1-10}-alkyl;

-C_{1-10} alkyl-O-C_{2-10} alkenyl; and

-C_{1-10} alkyl or C_{2-10} alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-CO-$N(R_3)_2$;

-CO-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each R_3 is independently selected from the group consisting of hydrogen and C_{1-10} alkyl; and

each **R** is independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, halogen and trifluoromethyl,

or a pharmaceutically acceptable salt thereof.

11. A compound according to Claim 10 wherein R_1 is selected from the group consisting of C_{1-6} alkyl and C_{1-6} hydroxyalkyl.

12. A compound according to Claim 11 wherein R_1 is selected from the group consisting of n-butyl, 2-hydroxy-2-methylpropyl, and 2-methylpropyl.

13. A compound according to Claim 10 wherein R_2 is selected from the group consisting of methyl, n-butyl, benzyl, ethoxymethyl, and methoxyethyl.

14. A compound according to Claim 10 wherein each R is hydrogen.

15. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to Claim 10 and a pharmaceutically acceptable carrier.

17. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound according to Claim 1 to the animal.

18. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound according to Claim 10 to the animal.

19. A method of treating a viral infection in an animal comprising admistering an effective amount of a compound according to claim 1 to the animal.

20. A method of treating a viral infection man animal comprising administering an effective amount of a compounds according to claim 10 to the aminal.

21. A compound of formula



wherein

A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or =CR-CR=CR-N=;

$\mathbf{R_1}$ is selected from the group consisting of:

- hydrogen;

-C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20}alkyl)$_{0-1}$-aryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$ -C_{1-20} alkyl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; and

-C_{1-20} alkyl-NR_3-Q-X-R_4 or -C_{2-20} alkenyl-NR_3-Q-X-R_4 wherein **Q** is –CO- or –SO_2-; **X** is a bond, -O- or -NR_3- and $\mathbf{R_4}$ is aryl; heteroaryl; heterocyclyl; or -C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20}alkyl)$_{0-1}$-aryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$ -C_{1-20} alkyl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-NR_3-CO-O-C_{1-20}alkyl;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; or R_4 is



wherein **Y** is –N- or –CR-;

R_2 is selected from the group consisting of:

-hydrogen;

-C_{1-10} alkyl;

-C_{2-10} alkenyl;

-aryl

-C_{1-10} alkyl -O-C_{1-10}-alkyl;

-C_{1-10} alkyl-O-C_{2-10} alkenyl; and

-C_{1-10} alkyl or C_{2-10} alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-$CO\text{-}N(R_3)_2$;

-$CO\text{-}C_{1\text{-}10}$ alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each $\mathbf{R_3}$ is independently selected from the group consisting of hydrogen and $C_{1\text{-}10}$ alkyl; and

each **R** is independently selected from the group consisting of hydrogen, $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkoxy, halogen and trifluoromethyl,

or a pharmaceutically acceptable salt thereof.

22. A compound of formula



wherein

$\mathbf{R_1}$ is selected from the group consisting of:

- hydrogen;

-$C_{1\text{-}20}$ alkyl or $C_{2\text{-}20}$ alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-$O\text{-}C_{1\text{-}20}$ alkyl,

-$O\text{-}(C_{1\text{-}20}\text{alkyl})_{0\text{-}1}$-aryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heteroaryl;
-O-(C_{1-20}alkyl)$_{0-1}$-heterocyclyl;
-C_{1-20} alkoxycarbonyl;
-S(O)$_{0-2}$ -C_{1-20} alkyl;
-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-aryl;
-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heteroaryl;
-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;
-N(R_3)$_2$;
-N_3;
oxo;
-halogen;
-NO_2;
-OH; and
-SH; and

-C_{1-20} alkyl-NR_3-Q-X-R_4 or -C_{2-20} alkenyl-NR_3-Q-X-R_4 wherein **Q** is –CO- or –SO_2-; **X** is a bond, -O- or -NR_3- and $\mathbf{R_4}$ is aryl; heteroaryl; heterocyclyl; or -C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consiting of:

-aryl;
-heteroaryl;
-heterocyclyl;
-O-C_{1-20} alkyl,
-O-(C_{1-20}alkyl)$_{0-1}$-aryl;
-O-(C_{1-20}alkyl)$_{0-1}$-heteroaryl;
-O-(C_{1-20}alkyl)$_{0-1}$-heterocyclyl;
-C_{1-20} alkoxycarbonyl;
-S(O)$_{0-2}$ -C_{1-20} alkyl;
-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-aryl;
-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heteroaryl;
-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;
-N(R_3)$_2$;

-NR_3-CO-O-C_{1-20}alkyl;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; or R_4 is



wherein **Y** is –N- or –CR-;

$\mathbf{R_2}$ is selected from the group consisting of:

-hydrogen;

-C_{1-10} alkyl;

-C_{2-10} alkenyl;

-aryl;

-C_{1-10} alkyl -O-C_{1-10}-alkyl;

-C_{1-10} alkyl-O-C_{2-10} alkenyl; and

-C_{1-10} alkyl or C_{2-10} alkenyl substituted by one or more substituents selected from the group consiting of:

-OH;

-halogen;

-$N(R_3)_2$;

-CO-$N(R_3)_2$;

-CO-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each R_3 is independently selected from the group consisting of hydrogen and C_{1-10} alkyl; and

each **R** is independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, halogen and trifluoromethyl,

or a pharmaceutically acceptable salt thereof.

23. A compound of formula



wherein

R_1 is selected from the group consisting of:

- hydrogen;

-C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20}alkyl)$_{0-1}$-aryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$ -C_{1-20} alkyl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH;

-C_{1-20} alkyl-NR_3-Q-X-R_4 or -C_{2-20} alkenyl-NR_3-Q-X-R_4 wherein **Q** is –CO- or –SO_2-; **X** is a bond, -O- or -NR_3- and $\mathbf{R_4}$ is aryl; heteroaryl; heterocyclyl; or -C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20}alkyl)$_{0-1}$-aryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$ -C_{1-20} alkyl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-NR_3-CO-O-C_{1-20}alkyl;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; or R_4 is



wherein **Y** is –N- or –CR-;

$\mathbf{R_2}$ is selected from the group consisting of:

-hydrogen;

-C_{1-10} alkyl;

-C_{2-10} alkenyl;

-aryl;

-C_{1-10} alkyl -O-C_{1-10}-alkyl;

-C_{1-10} alkyl-O-C_{2-10} alkenyl; and

-C_{1-10} alkyl or C_{2-10} alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-CO-$N(R_3)_2$;

-CO-C_{1-10} alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each $\mathbf{R_3}$ is independently selected from the group consisting of hydrogen and C_{1-10} alkyl; and

each **R** is independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, halogen and trifluoromethyl,

or a pharmaceutically acceptable salt thereof.

24. A compound of formula



wherein

A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or =CR-CR=CR-N=;

$\mathbf{R_7}$ is OH, halogen, or NHR_1,

$\mathbf{R_1}$ is selected from the group consisting of:

- hydrogen;

-C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20}alkyl)$_{0-1}$-aryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-$S(O)_{0-2}$ -C_{1-20} alkyl;

-$S(O)_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-aryl;

-$S(O)_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-$S(O)_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-$N(R_3)_2$;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; and

-C_{1-20} alkyl-NR_3-Q-X-R_4 or -C_{2-20} alkenyl-NR_3-Q-X-R_4 wherein **Q** is –CO- or –SO_2-; **X** is a bond, -O- or -NR_3- and $\mathbf{R_4}$ is aryl; heteroaryl; heterocyclyl; or -C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl,

-O-(C_{1-20}alkyl)$_{0-1}$-aryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$ -C_{1-20} alkyl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-NR_3-CO-O-C_{1-20}alkyl;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; or R_4 is



wherein **Y** is –N- or –CR-;

R_8 is H, NO_2 or NH_2; and

each **R** is independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof.

25. A compound of formula



wherein

A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or =CR-CR=CR-N= and

R_9 is H or C_{1-10} alkyl.

26. A compound of formula



wherein

R_1 is selected from the group consisting of:

-C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl;

-O-(C_{1-20}alkyl)$_{0-1}$-aryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$ -C_{1-20} alkyl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH;

-C_{1-20} alkyl-NR_3-Q-X-R_4 or -C_{2-20} alkenyl-NR_3-Q-X-R_4 wherein **Q** is –CO- or –SO_2-; **X** is a bond, -O- or -NR_3- and $\mathbf{R_4}$ is aryl; heteroaryl; heterocyclyl; or -C_{1-20} alkyl or C_{2-20} alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

-aryl;

-heteroaryl;

-heterocyclyl;

-O-C_{1-20} alkyl;

-O-(C_{1-20}alkyl)$_{0-1}$-aryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heteroaryl;

-O-(C_{1-20}alkyl)$_{0-1}$-heterocyclyl;

-C_{1-20} alkoxycarbonyl;

-S(O)$_{0-2}$ -C_{1-20} alkyl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-aryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heteroaryl;

-S(O)$_{0-2}$ –(C_{1-20} alkyl)$_{0-1}$-heterocyclyl;

-N(R_3)$_2$;

-NR_3-CO-O-C_{1-20}alkyl;

-N_3;

oxo;

-halogen;

-NO_2;

-OH; and

-SH; or R_4 is



wherein **Y** is –N- or –CR-;

each $\mathbf{R_3}$ is independently selected from the group consisting of hydrogen and C_{1-10} alkyl;

each **R** is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, halogen and trifluoromethyl; and

$\mathbf{R_{10}}$ is $-NO_2$ or NH_2;

or a pharmaceutically acceptable salt thereof.